Advertisement

Topics

High-throughput Assay to Identify New Cancer Drugs

14:37 EDT 12 Jul 2018 | NIH

 The National Cancer Institute seeks parties interested in collaborative research to evaluate or commercialize a diagnostic tool that can identify new drugs that increase chromosome instability.  Although chromosomal instability is generally thought of as a driver of tumor growth, a threshold level exists where CIN becomes a barrier to tumor growth and therefore can be exploited therapeutically.

Most human malignant solid tumors have been shown to contain chromosomal abnormalities.  Chromosomal instability (CIN) is the continuous formation of novel chromosome mutations at a higher rate than that of normal cells. Although chromosomal instability (CIN) is generally thought of as a driver of tumor growth, a threshold level exists where CIN becomes a barrier to tumor growth and therefore can be exploited therapeutically. Drugs known to increase CIN beyond the therapeutic threshold are currently few in number, and the clinical promise of targeting the CIN phenotype warrants new screening efforts.

Researchers at NCI developed a new high-throughput assay for measuring CIN as a tool to identify new compounds that increase CIN in cancer cells and therefore have therapeutic potential.  The assay uses a unique, green fluorescent protein (GFP)-labeled human artificial chromosome (HAC) that can be introduced into cancer cells. Drug effects on CIN in cells containing the GFP-labeled HAC can be identified easily and accurately by flow cytometry.

IC: 
NCI
NIH Ref. No.: 
E-031-2013
Advantages: 

High-throughput format allows for rapid screening of large numbers of compounds

Applications: 

Screening tool to identify compounds that increase CIN in cancer cells for the development of new therapeutic strategies.

Development Status: 

Prototype

Updated On: 
May 30, 2018
Provider Classifications: 
Publications: 
Licensing Contacts: 
Lead Inventor: 
Inventor IC: 
NCI
NCI
Inventor Lab URL: 
https://ccr.cancer.gov/Developmental-Therapeutics-Branch/vladimir-l-larionov
LPM FIrst Name: 
John
LPM Last Name: 
Hewes
Inv Is lead: 
LPM Phone: 
240-276-5515
LPM Suffix: 
Ph.D.
LPM Organization: 
NCI - National Cancer Institute
DTDT Classification: 
Diagnostics
Research Materials
DTDT Description: 
Diagnostics
Research Materials
Collaboration Sought: 
Yes
Institute or Center: 
Collaboration Opportunity: 

Licensing only

E Number Only: 
E-031-2013
Inventor First Name: 
Vladimir
William
Inventor Last Name: 
Larionov
Earnshaw

Original Article: High-throughput Assay to Identify New Cancer Drugs

NEXT ARTICLE

More From BioPortfolio on "High-throughput Assay to Identify New Cancer Drugs"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Cancer Disease
Cancer is not just one disease but many diseases. There are more than 100 different types of cancer. Most cancers are named for the organ or type of cell in which they start - for example, cancer that begins in the colon is called colon cancer; cancer th...

Bioinformatics
Bioinformatics is the application of computer software and hardware to the management of biological data to create useful information. Computers are used to gather, store, analyze and integrate biological and genetic information which can then be applied...

Assays
An assay is an analytic procedure for qualitatively assessing or quantitatively measuring the presence or amount or the functional activity of a target entity.  This can be a drug or biochemical substance or a cell in an organism or organic sample. ...